BUZZ-Ideaya rises as FDA clears trial for experimental cancer drug
Ideaya Biosciences' shares rise 3.3% as the FDA clears its first human trial for IDE034, an experimental cancer drug targeting B7H3 and PTK7 proteins in common solid tumors. IDE034 showed strong effects in animal studies, both alone and with IDE161. Patient enrollment starts Q1 2026, with more data expected in H1 2026. Stock up ~39% YTD.
Shares of California-based drug developer Ideaya Biosciences (IDYA.O) rise 3.3% to $36.80 premarket
Co says it has received clearance from U.S. FDA to begin its first human trial on its new experimental cancer drug, IDE034, which is designed to target several common types of solid tumors
Drug targets B7H3 and PTK7 proteins, often found together in lung, colorectal and head & neck cancers - IDYA
Co says these proteins are present in up to 46% of colorectal cancers, 30% of lung cancers, and 27% of head and neck cancers
In animal studies, IDE034 showed strong tumor-fighting effects, both on its own and when combined with co’s another drug, IDE161 - IDYA
Co to begin enrolling patients in Q1 2026; more data expected at H1 2026 medical meeting
Up to last close, stock up ~39% YTD
